Diplomat to Dispense AstraZeneca Drug IRESSA®
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/14/2026
- S&P 500, Dow futures dip as big banks' earnings roll in ahead of CPI data; IBM slides
- IBM plunges 19% as memory capex squeeze derails Q2 earnings
- SK Hynix’s record plunge drags down global chip stocks
- Software stocks tumble: High memory prices cannibalize enterprise tech capex
- Oil up 9% to one-month high as US says it will blockade entire Iranian coastline, all vessels
- IBM misses Q2 targets as mainframe and software sales disappoint
- Goldman Sachs Upgrades NIO (NIO) to Buy
- BofA Securities on AppLovin: 'Current valuation appears reasonable'
- Wall Street ends lower as Iran tensions dampen risk appetite; chipmakers drop
- YPF Energía Eléctrica S.A. files for proposed NYSE IPO
Diplomat Pharmacy (DPLO) Will Begin Offering IRESSA (AZN)
August 10, 2015 5:09 PM EDTDiplomat Pharmacy (NYSE: DPLO) announced that it will offer IRESSA (gefitinib), recently approved by the U.S. Food and Drug Administration as a first-line therapy for a specific type of metastatic non-small cell lung cancer (NSCLC).
IRESSA is a once-daily oral medication that targets and blocks the activity of epidermal growth factor receptor-tyrosine kinase (EGFR-TK), an enzyme that regulates the intracellular signaling... More
